Kyle Pedro

Kyle Pedro is a Scientist II at Caribou Biosciences since October 2023 and previously served as a Senior Scientist at Obsidian Therapeutics from November 2020 to October 2023, focusing on the characterization and evaluation of OBX-115, a membrane-bound IL15-engineered tumor infiltrating lymphocyte. Prior roles include Postdoctoral Researcher and Graduate Student Researcher at Boston University School of Medicine, where a Ph.D. in Microbiology and Immunology was obtained from 2014 to 2020. Additional experience includes various research positions at Fred Hutchinson Cancer Research Center and UC Davis. Educational background includes a Bachelor of Science in Biochemistry from the University of California, Davis, completed in 2010.